Brief: FDA Approves Brinsupri As First Treatment For Non-Cystic Fibrosis Bronchiectasis

Insmed

12/08/2025 18:32

Aug 12 (Reuters) - Insmed Inc INSM.O:

FDA APPROVES BRINSUPRI™ (BRENSOCATIB) AS THE FIRST AND ONLY TREATMENT FOR NON-CYSTIC FIBROSIS BRONCHIECTASIS, A SERIOUS, CHRONIC LUNG DISEASE

INSMED INC - BRINSUPRI 10 MG AND 25 MG DOSES APPROVED FOR NCFB

INSMED INC -  PLANS TO FILE APPLICATIONS FOR BRENSOCATIB IN JAPAN IN 2025

Source text: ID:nPn34v3m3a

Further company coverage: INSM.O

 ((Reuters.Briefs@thomsonreuters.com;))